About Abbott Molecular   
Abbott's rapidly growing molecular diagnostics business provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression.  The business includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA.  In 2002, Abbott formed an alliance with Celera Diagnostics focused on developing and marketing a broad menu of next-generation molecular diagnostics products for unmet medical and laboratory needs. 

Abbott offers innovative genomic tests for chromosome changes associated with congenital disorders and cancer, including the Vysis PathVysion® HER-2 DNA Probe kit to identify women with metastatic breast cancer who could benefit from Herceptin® therapy, and UroVysion®, which detects genetic changes in bladder cells for use in monitoring bladder cancer recurrence and for use as an aid in the initial diagnosis of bladder cancer in patients with hematuria (blood in urine) suspected of having bladder cancer.